Background
Melanoma
DISEASE, MELANOMA, OF SKIN CANCER, METASTATIC MELANOMA
Melanoma was recognized as the most dangerous type of skin cancer, especially for metastatic melanoma. Before 2011, metastatic melanoma was considered a devastating disease, the standard-of-care treatments during this time included dacarbazine chemotherapy and immunotherapy with the cytokine IL-2, and the median overall survival was only 9 months. Fortunately, the treatment landscape has shifted dramatically during recent years [After HL-085 is an orally active, selective MEK inhibitor that suppresses MEK1 activity with a half-maximal inhibitory concentration (ICThis phase I trial was first-in-human trial to evaluate the tolerability, preliminary efficacy, pharmacokinetics of HL-085 in patients with advanced 